Skip to main content

Table 3 Twelve months outcomes after cART initiation according to treatments that did/did not follow the guidelines

From: The effect of adherence to guidelines for initial antiretroviral therapy on 1-year outcomes: a French cohort study

  All population "when-to-start" guidelines "what-to-start" guidelines
Characteristic N = 1,365 Followed guidelines (n = 1,214) Outside of guidelines (n = 151) P Followed guidelines (n = 1,215) Outside of guidelines (n = 150) P
cART modification (%) 43.6 43.7 43.4 - 41.2 62.7 <0.001
12 months CD4 (/mm3) (median [IQR]) 395 369 619 <0.001 406 313 <0.001
[241-538] [224-506] [504-766] [257-548] [148-484]
CD4 gain (/mm3) (median [IQR]) 137 139 89 0.006 144 69 <0.001
[33-238] [39-239] [0-216] [40-239] [0-204]
12 months HIV-RNA (log copies/mL) (median [IQR]) 1.7 1.7 1.7 - 1.7 1.9 <0.001
[1.6-2.3] [1.6-2.3] [1.7-2.4] [1.6-2.2] [1.7-3.4]
HIV-RNA <50 copies/mL (%) 64.6 64.3 66.9 - 66.8 47.3 <0.001
Deceased (%) 0.8 0.9 0 - 0.6 2.7 0.007
  1. Abbreviations: IQR interquartile range, cART combined antiretroviral therapy, HIV human immunodeficiency virus.